No Data
Beijing Balance Medical Technology Co., Ltd. (688198.SH): The pulmonary artery valve and delivery system have entered the special review process for Innovative Medical Management.
On January 3, Longhu announced that Beijing Balance Medical Technology Co., Ltd. (688198.SH) has received approval from the Medical Device Technical Evaluation Center of the National Medical Products Administration for the self-developed first all-comer interventional pulmonary valve and delivery system, entering the special review procedure for innovative medical instruments. The company's interventional pulmonary valve and delivery system is designed for patients who need catheter artificial biological pulmonary valve replacement after surgical right ventricle outflow tract repair and reconstruction due to complex congenital heart disease. This product is the third interventional valve product of the company to enter the special review procedure for innovative medical instruments, and it also manages the full lifecycle of pulmonary valve patients.
Beijing Balance Medical Technology Co., Ltd. (688198.SH): The registration application for ophthalmic biological patches has been accepted.
beijing balance medical technology co., ltd. (688198.SH) announced that the registration application of the ophthalmic biological patch product developed by the company has been approved recently...
Beijing Balance Medical Technology Co., Ltd. (688198.SH): Application for pericardial membrane registration has been accepted.
Gelonghui, November 19 - Beijing Balance Medical Technology Co., Ltd. (688198.SH) announced that the registration application for the ePTFE pericardium developed by the company has been officially accepted by the National Medical Products Administration. This product is manufactured using a special process to create an expanded polytetrafluoroethylene (ePTFE) membrane, which is used for the repair or reconstruction of the pericardium in cardiac surgery.
Bairen Healthcare Third Quarter Report 2024
beijing balance medical technology co., ltd. (688198.SH): The net income in the first three quarters was 58.6934 million yuan, a year-on-year decrease of 16.56%.
On October 29, beijing balance medical technology co., ltd. (688198.SH) announced that in the first three quarters of 2024, it achieved a total operating income of 0.292 billion yuan, a year-on-year increase of 13.57%; the net income attributable to shareholders of the parent company decreased by 16.56% to 58.6934 million yuan; the basic earnings per share was 0.43 yuan.
Has the source of funds for the controlling shareholder's shareholding changed? Beijing Balance Medical Technology Co., Ltd. insider: Self-financing can also be done through "special shareholding loans".
①Company insiders have expressed that beijing balance medical technology co., ltd. plans to increase its shareholding through self-raised funds, not ruling out the possibility of increasing company stocks through bank's "stock shareholding special loans". ②Jin Lei, the director of beijing balance medical technology co., ltd., believes that against the backdrop of a sluggish performance in the medical instruments sector, the company's stock price is undervalued by the market.
